ArriVent Biopharma is Pharmaceuticals in United States that focus on developer business. Founded in 2021. They cover business area such as developer, pharmaceutical product, presently untreatable cancer, manufacturing, commercialization, target cancer therapy, furmonertinib, non-small-cell lung cancer, potentially other solid tumor, patient, therapeutic treatment.
2021
( 3 years old in 2024 )
Developer
-
18 Campus Boulevard
Suite 100
Newtown Square, PA 19073-3269
United States
Private
developerpharmaceutical productpresently untreatable cancermanufacturingcommercializationtarget cancer therapyfurmonertinibnon-small-cell lung cancerpotentially other solid tumorpatienttherapeutic treatment
* We use standard office opening hours in near ArriVent Biopharma's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
ArriVent Biopharma is Pharmaceuticals business from United States that founded in 2021 (3 years old in 2024), ArriVent Biopharma business is focusing on Developer.
ArriVent Biopharma headquarter office and corporate office address is located in 18 Campus Boulevard Suite 100 Newtown Square, PA 19073-3269 United States.
ArriVent Biopharma was founded in United States.
In 2024, ArriVent Biopharma is currently focus on developer sector.
Above is snippet of Google Trends for "developer" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with ArriVent Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.